The cost of cancer care: Part I

ONCOLOGY (United States)

Volumn 26, Issue 10, 2012, Pages

  Eagle, David ^a  

^a Lake Norman Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IPILIMUMAB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; SIPULEUCEL T;

CANCER PATIENT; COLON CANCER; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST CONTROL; DEMOGRAPHY; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH INSURANCE; HOSPITAL COST; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; MELANOMA; OVERALL SURVIVAL; PRESCRIPTION; PREVALENCE; PROSTATE CANCER; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84874604913     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Greenberg D, Earle C, Chi-Hui F, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102:82-8.
2. Pauly M. Is high and growing spending on cancer treatment and prevention harmful to the United States economy? J Clin Oncol. 2007:25:171-4.
3. Yabroff K, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011;20:2006-14.
4. Tangka F, Trogdon J, Richardson R, et al. Cancer treatment costs in the United States. Cancer. 2010;116:3477-84.
5. Institute of Medicine: Assessing and improving value in cancer care: workshop summary. Washington, DC, The National Academies Press, 2009. Available from http://www.nap.edu/catalog.php?record_id=12644.
6. Site of service cost differences for Medicare patients receiving chemotherapy. Milliman Client Report. Oct 19, 2011. Available http://www.communityoncology.org/UserFiles/pdfs/milliman-site-of-service-cost-differences-medicare-report.pdf.
7. Total cost of cancer care by site of service: physician office vs outpatient hospital. March 2012. Available http://admin.communityoncology.org/UserFiles/files/Avalere_Cost%20of_Cancer_Care_StudyF(2).pdf.
8. Mariotto A, Yabroff R, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-28.
9. Bach P. Limits on Medicares ability to control rising spending on cancer drugs. N Engl J Med. 2009;360: 626-33.
10. Schrag D. The price tag on progress chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-19.
11. Karaca-Mandic P, McCullough J, Siddiqui M, et al. Impact of new drugs and biologicals on colorectal cancer treatment and costs. J Oncol Pract. 2011;7(3 Suppl):e30s-7s.
12. DiMasi J, Hansen R, Grabowski H. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
13. Adams C, Brantner V. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood). 2006;25:420-8.
14. Streeter S, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncology prescriptions. J Oncol Pract. 2011;7(3 Suppl):46s-51s.
15. Kim P. Cost of cancer care: the patient perspective. J Clin Oncol. 2007;25:228-32.
16. Himmelstein D, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122:741-6.
17. USA Today, Kaiser Family Foundation, Harvard School of Public Health: National survey of households affected by cancer. November 2006. Available from http://www.kff.org/kaiserpolls/7590.cfm.
18. Romley JA, Sanchez Y, Penron JR, Goldman DP. Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs. Health Aff (Millwood). 2012;31:683-90.
19. Weinfurt K. Value of high-cost cancer care: a behavorial science perspective. J Clin Oncol. 2007; 25:223-7.
20. Lakdawalla D, Romley J, Sanchez Y, et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31:676-82.
21. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293.
22. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 Blockade with ipilimumab: long-term follow up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039.